Connor Quinn
Publication Activity (10 Years)
Years Active: 2024-2024
Publications (10 Years): 5
Publications (10 Years): 5
Publications
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C Taylor
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
- Sheryl M Gough, John J Flanagan, Jessica L F Teh, Monica Andreoli, Emma Rousseau, Melissa Pannone, Mark Bookbinder, Ryan Willard, Kim Davenport, Elizabeth Bortolon, Gregory Cadelina, Deborah Gordon, Jennifer Pizzano, Jennifer Macaluso, Leofal Soto, John P Corradi, Katherine M Digianantonio, Ieva Drulyte, Alicia Morgan, Connor Quinn, Miklós Békés, Caterina Ferraro, Xin Chen, Gan Wang, Hanqing Dong, Jing Wang, David R Langley, John Houston, Richard Gedrich, Ian C TaylorOral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)